COMPANY

Vaccinex

HQ: Rochester, NY source · vaccinex.com ↗ · Mid-Atlantic

Location: Rochester, NY · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: prostate cancer breast cancer Metastatic Pancreatic Adenocarcinoma Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Alzheimer Disease Non-Small-Cell Lung Carcinoma Huntington's Disease Multiple Sclerosis osteoporosis VX15/2503 Pepinemab

7Trials (company is sponsor)19NIH grants

Timeline

Dec 10, 2022 Trial start Phase 1/Phase 2: Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma source ↗
Aug 9, 2021 Trial start Phase 1/Phase 2: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck source ↗
Jul 22, 2021 Trial start Phase 1/Phase 2: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD) source ↗
Oct 5, 2017 Trial start Phase 1/Phase 2: VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer source ↗
2015-07 Trial start Phase 2: A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi source ↗
2012-12 Trial start Phase 1: Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS source ↗
2011-01 Trial start Phase 1: Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors source ↗

Upcoming milestones

Dec 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma · NCT05102721

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT05102721	Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma	Phase 1/Phase 2	Active, not recruiting	Dec 10, 2022	Dec 31, 2028 (estimated)
NCT04815720	Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	Phase 1/Phase 2	Completed	Aug 9, 2021	Jul 24, 2024 (actual)
NCT04381468	SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)	Phase 1/Phase 2	Completed	Jul 22, 2021	Jun 5, 2024 (actual)
NCT03268057	VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer	Phase 1/Phase 2	Completed	Oct 5, 2017	Sep 9, 2020 (actual)
NCT02481674	A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi	Phase 2	Completed	2015-07	2020-08 (actual)
NCT01764737	Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS	Phase 1	Completed	2012-12	2014-11 (actual)
NCT01313065	Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors	Phase 1	Completed	2011-01	2014-06 (actual)

NIH awards 19

Annual award amounts. Total $5.2M.

Apr 20, 2005 NIH award 5R43CA108032-02 FY2005: $295,926 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, ERNEST S; recipient as written: VACCINEX, INC., ROCHESTER, NY. New Target Antigens for Prostate Cancer Immunothe source ↗
Apr 11, 2005 NIH award 5R43AI056624-02 FY2005: $717,652 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, ERNEST S; recipient as written: VACCINEX, INC., ROCHESTER, NY. Human Monoclonal Antibodies for Bioterrorism Defe source ↗
Feb 24, 2005 NIH award 5R43CA105542-02 FY2005: $234,188 awarded for that fiscal year; activity R43 (SBIR); PI PARIS, MARK J; recipient as written: VACCINEX, INC., ROCHESTER, NY. Functional Identification of Cancer Regulators source ↗
May 14, 2004 NIH award 1R43AG025564-01 FY2004: $217,632 awarded for that fiscal year; activity R43 (SBIR); PI PARIS, MARK J; recipient as written: VACCINEX, INC., ROCHESTER, NY. Monoclonal Antibody Therapy to Combat Osteoporosis source ↗
Apr 27, 2004 NIH award 1R43CA108032-01 FY2004: $303,809 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, ERNEST S; recipient as written: VACCINEX, INC., ROCHESTER, NY. New Target Antigens for Prostate Cancer Immunothe source ↗
Apr 14, 2004 NIH award 1R43AI056624-01A1 FY2004: $641,026 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, ERNEST S; recipient as written: VACCINEX, INC., ROCHESTER, NY. Human Monoclonal Antibodies for Bioterrorism De source ↗
Mar 2, 2004 NIH award 5R43CA099113-02 FY2004: $216,700 awarded for that fiscal year; activity R43 (SBIR); PI ZAUDERER, MAURICE; recipient as written: VACCINEX, INC., ROCHESTER, NY. A METHOD TO IDENTIFY UPSTREAM REGULATORS OF ONC source ↗
Feb 13, 2004 NIH award 1R43CA105542-01 FY2004: $178,861 awarded for that fiscal year; activity R43 (SBIR); PI PARIS, MARK J; recipient as written: VACCINEX, INC., ROCHESTER, NY. Functional Identification of Cancer Regulators source ↗
Jul 15, 2003 NIH award 5R43AG020881-02 FY2003: $225,774 awarded for that fiscal year; activity R43 (SBIR); PI PARIS, MARK J; recipient as written: VACCINEX, INC., ROCHESTER, NY. Genetic Selection System to Clone Osteogenic Regula source ↗
2003 NIH award 1R43CA099113-01 FY2003: $216,700 awarded for that fiscal year; activity R43 (SBIR); PI ZAUDERER, MAURICE; recipient as written: VACCINEX, INC., ROCHESTER, NY. A METHOD TO IDENTIFY UPSTREAM REGULATORS OF ONC source ↗
Aug 23, 2002 NIH award 2R44CA080440-02 FY2001: $472,605 awarded for that fiscal year; activity R44 (SBIR); PI BORRELLO, MELINDA A; recipient as written: VACCINEX, INC., ROCHESTER, NY. C35: A Target for Bladder and Breast Cancer T source ↗
Jul 24, 2002 NIH award 5R44CA080440-03 FY2002: $436,055 awarded for that fiscal year; activity R44 (SBIR); PI BORRELLO, MELINDA A; recipient as written: VACCINEX, INC., ROCHESTER, NY. C35: A Target for Bladder and Breast Cancer T source ↗
May 13, 2002 NIH award 1R43AG020881-01 FY2002: $208,300 awarded for that fiscal year; activity R43 (SBIR); PI PARIS, MARK J; recipient as written: VACCINEX, INC., ROCHESTER, NY. Genetic Selection System to Clone Osteogenic Regula source ↗
Aug 17, 2001 NIH award 1R43AR048072-01 FY2001: $99,999 awarded for that fiscal year; activity R43 (SBIR); PI SMITH, ERNEST S; recipient as written: VACCINEX, INC., ROCHESTER, NY. Genetic Selection to Clone Chondrogenic Regulators source ↗
Feb 5, 2001 NIH award 5R43CA082948-02 FY2001: $238,912 awarded for that fiscal year; activity R43 (SBIR); PI BORRELLO, MELINDA A; recipient as written: VACCINEX, INC., ROCHESTER, NY. NEW TARGET ANTIGENS FOR PROSTATE CANCER VACCI source ↗
Feb 16, 2000 NIH award 1R43CA082948-01 FY2000: $238,912 awarded for that fiscal year; activity R43 (SBIR); PI BORRELLO, MELINDA A; recipient as written: VACCINEX, INC., ROCHESTER, NY. NEW TARGET ANTIGENS FOR PROSTATE CANCER VACCI source ↗
Jan 27, 2000 NIH award 1R43CA080440-01A2 FY2000: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI BORRELLO, MELINDA A; recipient as written: VACCINEX, INC., ROCHESTER, NY. GENE EXPRESSION AND IMMUNOGENS OF UROEPITHE source ↗
Feb 16, 1999 NIH award 3R43CA079372-01S1 FY1999: $65,880 awarded for that fiscal year; activity R43 (SBIR); PI ZAUDERER, MAURICE; recipient as written: VACCINEX, INC., ROCHESTER, NY. ANTIGENS OF BRONCHIAL EPITHELIAL TUMORS source ↗
Aug 21, 1998 NIH award 1R43CA079372-01 FY1998: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI ZAUDERER, MAURICE; recipient as written: VACCINEX, INC., ROCHESTER, NY. ANTIGENS OF BRONCHIAL EPITHELIAL TUMORS source ↗